Xanomeline-trospium: the first schizophrenia drug that skips dopamine

Xanomeline-trospium, sold as Cobenfy, is the first drug approved for schizophrenia that treats psychosis without blocking the dopamine D2 receptor — the mechanism shared by every antipsychotic before it [s3][s4]. The US Food and Drug Administration cleared it on 26 September 2024 after two five-week phase 3 trials in which it reduced symptom scores more than placebo, with a side-effect profile that trades the weight gain and movement disorders of older drugs for gastrointestinal and other cholinergic effects [s1][s2][s4].

How much of a change that turns out to be depends on questions the approval trials were not built to answer: they ran five weeks, enrolled acutely ill inpatients, and compared the drug with placebo rather than with an existing antipsychotic. This piece describes what the evidence shows and does not show; it is not advice, and nothing in it should be used to start, stop or change a medication.

A different mechanism

Every antipsychotic in use blunts psychosis by dampening dopamine signalling, which is also why the class causes movement disorders, sedation and metabolic harm. Xanomeline is a muscarinic receptor agonist — it activates M1 and M4 acetylcholine receptors in the brain and has no direct D2 dopamine-blocking activity [s1][s3]. On its own, xanomeline was abandoned decades ago because it caused too many peripheral cholinergic side effects; the new drug pairs it with trospium, a muscarinic antagonist that stays largely outside the brain and is meant to blunt those peripheral effects without cancelling the central benefit [s1][s3]. The FDA described it as a treatment with a new mechanism of action, the first in decades [s4].

What the trials showed

The signal first appeared in a phase 2 trial, EMERGENT-1, published in the New England Journal of Medicine in 2021: among 182 patients, the PANSS total symptom score fell 17.4 points on xanomeline-trospium against 5.9 on placebo over five weeks (least-squares mean difference −11.6, 95% CI −16.1 to −7.1; p<0.001) [s3].

Two phase 3 trials then repeated the result. In EMERGENT-2, published in The Lancet, 252 inpatients with acute psychosis were randomised to drug or placebo; PANSS total scores fell 21.2 points versus 11.6, a least-squares mean difference of −9.6 (95% CI −13.9 to −5.2; p<0.0001), with a moderate effect size (Cohen's d 0.61) [s1]. In EMERGENT-3, published in JAMA Psychiatry, 256 patients showed falls of 20.6 versus 12.2 points, a difference of −8.4 (95% CI −12.4 to −4.3; p<0.001; Cohen's d 0.60) [s2]. The two phase 3 trials were near-identical in design, which is part of why the consistent result carried weight [s1][s2].

The side effects are real, just different

The tolerability story is the drug's main selling point and its main asterisk. In EMERGENT-2, the common adverse events on xanomeline-trospium versus placebo were constipation (21% vs 10%), dyspepsia (19% vs 8%), nausea (19% vs 6%), vomiting (14% vs 1%) and hypertension (10% vs 1%) — a cholinergic and anticholinergic pattern, not the metabolic one of standard drugs [s1]. Rates of extrapyramidal motor symptoms (0% vs 0%) and weight gain (0% vs 1%) were no higher than placebo, and discontinuations for adverse events were similar between arms (7% vs 6%) [s1]. EMERGENT-3 showed the same shape, with nausea, dyspepsia, vomiting and constipation the most common events and discontinuation rates of 6.4% versus 5.5% [s2].

What the trials did not settle

The evidence has clear boundaries. All three trials lasted five weeks in patients hospitalised for acute psychosis, so durability, relapse prevention and long-term safety were not tested in these studies — the drug's maker deferred those to open-label extension trials [s1]. None of the trials compared xanomeline-trospium head-to-head against an existing antipsychotic, so the claim on offer is superiority to placebo, not to the drugs it might replace [s1][s2]. And the effect sizes, while consistent, are moderate rather than transformative [s1][s2]. The label carries the Cobenfy brand under application NDA 216158 [s5].

Why it matters

For a condition where a large share of patients stop their medication over intolerable side effects, a drug that works through a different receptor system — and appears to avoid weight gain and movement disorders — is a genuine addition rather than a reformulation, even before the long-term data arrive [s1][s4]. For the physical toll that antipsychotic side effects contribute to, see the mortality gap in serious mental illness; for the drug that has long anchored treatment-resistant schizophrenia, see clozapine across diagnoses; and for a non-drug approach to persistent voices, see VR therapy for auditory hallucinations.

Sources

• Efficacy and safety of KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) — The Lancet, 2023-12-14
• Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia (EMERGENT-3) — JAMA Psychiatry, 2024-05-01
• Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia (EMERGENT-1) — New England Journal of Medicine, 2021-02-24
• FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia — U.S. Food and Drug Administration, 2024-09-26
• Cobenfy (xanomeline and trospium chloride) — Drugs@FDA overview, NDA 216158 — U.S. Food and Drug Administration, 2024-09-26